Ghent University Academic Bibliography

Advanced

Efficacy of tilmicosin phosphate (Pulmotil((R)) premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs

Geert Hoflack UGent, B Maes, M Mateusen, A Verdonck and Aart de Kruif UGent (2001) JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH. 48(9). p.655-664
abstract
A double-blind randomized clinical trial was carried out to investigate the efficacy of tilmicosin (Pulmotil (R) premix) for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. The effects of tilmicosin administration in the feed at 400 mg/kg and an injection therapy of clinically diseased pigs with long-acting oxytetracycline (Terramycine (R) LA) at 20 mg/kg body-weight were compared. Both groups, totalling 147 pigs, were compared during a medication period of 15 days and a post-medication period of 11 days by means of different clinical and performance parameters. During the medication period, the tilmicosin group showed a significant advantage with respect to the number of new disease cases (P < 0.01), and a nonsignificant advantage regarding the number of removed pigs (P = 0.16), the number of sick pigs that recovered (P = 0.27) and the time to recovery (P = 0.42). During the post-medication period, the pigs of the tilmicosin group showed numerical non-significant benefits (P > 0.05) with respect to the clinical parameters. During the overall study period (26 days), the average daily gain and the feed conversion ratio were both significantly (P < 0.01) better in pigs from the tilmicosin group compared with pigs from the oxytetracycline group. This study demonstrated that in-feed medication of tilmicosin at a dosage of 400 mg/kg is efficacious for the treatment of a clinical respiratory disease outbreak of A. pleuropneumoniae infection in growing-finishing pigs. Compared with oxytetracycline injection of clinically diseased pigs, the tilmicosin treatment is particularly, beneficial in the prevention of new disease cases while increasing or maintaining the performance the pigs.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PORCINE PLEUROPNEUMONIA, ANTIBACTERIAL PROPERTIES, PASTEURELLA-MULTOCIDA, SWINE, SUSCEPTIBILITY, DISEASE, EL-870
journal title
JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH
J. Vet. Med. Ser. B-Infect. Dis. Vet. Public Health
volume
48
issue
9
pages
655 - 664
Web of Science type
Article
Web of Science id
000172878000003
JCR category
VETERINARY SCIENCES
JCR impact factor
0.551 (2001)
JCR rank
52/126 (2001)
JCR quartile
2 (2001)
ISSN
0931-1793
DOI
10.1046/j.1439-0450.2001.00492.x
language
English
UGent publication?
yes
classification
A1
id
146235
handle
http://hdl.handle.net/1854/LU-146235
date created
2004-01-14 13:38:00
date last changed
2016-12-19 15:37:50
@article{146235,
  abstract     = {A double-blind randomized clinical trial was carried out to investigate the efficacy of tilmicosin (Pulmotil (R) premix) for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. The effects of tilmicosin administration in the feed at 400 mg/kg and an injection therapy of clinically diseased pigs with long-acting oxytetracycline (Terramycine (R) LA) at 20 mg/kg body-weight were compared. Both groups, totalling 147 pigs, were compared during a medication period of 15 days and a post-medication period of 11 days by means of different clinical and performance parameters. During the medication period, the tilmicosin group showed a significant advantage with respect to the number of new disease cases (P {\textlangle} 0.01), and a nonsignificant advantage regarding the number of removed pigs (P = 0.16), the number of sick pigs that recovered (P = 0.27) and the time to recovery (P = 0.42). During the post-medication period, the pigs of the tilmicosin group showed numerical non-significant benefits (P {\textrangle} 0.05) with respect to the clinical parameters. During the overall study period (26 days), the average daily gain and the feed conversion ratio were both significantly (P {\textlangle} 0.01) better in pigs from the tilmicosin group compared with pigs from the oxytetracycline group. This study demonstrated that in-feed medication of tilmicosin at a dosage of 400 mg/kg is efficacious for the treatment of a clinical respiratory disease outbreak of A. pleuropneumoniae infection in growing-finishing pigs. Compared with oxytetracycline injection of clinically diseased pigs, the tilmicosin treatment is particularly, beneficial in the prevention of new disease cases while increasing or maintaining the performance the pigs.},
  author       = {Hoflack, Geert and Maes, B and Mateusen, M and Verdonck, A and de Kruif, Aart},
  issn         = {0931-1793},
  journal      = {JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH},
  keyword      = {PORCINE PLEUROPNEUMONIA,ANTIBACTERIAL PROPERTIES,PASTEURELLA-MULTOCIDA,SWINE,SUSCEPTIBILITY,DISEASE,EL-870},
  language     = {eng},
  number       = {9},
  pages        = {655--664},
  title        = {Efficacy of tilmicosin phosphate (Pulmotil((R)) premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs},
  url          = {http://dx.doi.org/10.1046/j.1439-0450.2001.00492.x},
  volume       = {48},
  year         = {2001},
}

Chicago
Hoflack, Geert, B Maes, M Mateusen, A Verdonck, and Aart de Kruif. 2001. “Efficacy of Tilmicosin Phosphate (Pulmotil((R)) Premix) in Feed for the Treatment of a Clinical Outbreak of Actinobacillus Pleuropneumoniae Infection in Growing-finishing Pigs.” Journal of Veterinary Medicine Series B-infectious Diseases and Veterinary Public Health 48 (9): 655–664.
APA
Hoflack, G., Maes, B., Mateusen, M., Verdonck, A., & de Kruif, A. (2001). Efficacy of tilmicosin phosphate (Pulmotil((R)) premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH, 48(9), 655–664.
Vancouver
1.
Hoflack G, Maes B, Mateusen M, Verdonck A, de Kruif A. Efficacy of tilmicosin phosphate (Pulmotil((R)) premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH. 2001;48(9):655–64.
MLA
Hoflack, Geert, B Maes, M Mateusen, et al. “Efficacy of Tilmicosin Phosphate (Pulmotil((R)) Premix) in Feed for the Treatment of a Clinical Outbreak of Actinobacillus Pleuropneumoniae Infection in Growing-finishing Pigs.” JOURNAL OF VETERINARY MEDICINE SERIES B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH 48.9 (2001): 655–664. Print.